Australia's AnteoTech slips on delayed registration for its COVID test kit

Anteotech

10/02/2022 02:17

** Shares of the nanotechnology firm  ADO.AX  skid as much
as 14.9% to A$0.200, on track for their sharpest single-day pct
decline since Jan 31 
    ** AnteoTech highlights the requirement of additional
clinical evidence for the registration of its EuGeni Reader used
with SARS CoV-2 Rapid Diagnostic Test with Australia's
Therapeutic Goods Administration (TGA)  urn:newsml:reuters.com:*:nASXbGNHkx
    ** AnteoTech intends to collect further clinical data based
on samples collected directly from patients for its new
submission with the TGA
    ** Shares hit their lowest levels since Feb 1 
    ** More than 13.7 mln shares change hands as compared with
the 30-day average volume of ~10.9 mln shares  
    ** Stock down 23% this year, as of last close 


 (Reporting by Roushni Nair in Bengluru)
 ((Roushni.Nair@thomsonreuters.com;))